A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance

Pancreatic cancer cured in mice? Why researchers still urge caution

In recent months, an experimental study conducted by the group led by Mariano Barbacid has received considerable media attention following reports of complete regression of pancreatic tumors in mouse models. Given the very poor prognosis associated with pancreatic cancer, this public interest is understandable. At the same time, these findings should be interpreted in a balanced and scientific manner. The study represents preclinical basic research that is biologically informative but is still far from clinical application in humans.
The study focuses on pancreatic ductal adenocarcinoma (PDAC). A defining feature of these tumors is the presence of activating mutations in the KRAS gene in more than 90% of cases. KRAS is a central signaling molecule that regulates cellular growth and proliferation, and oncogenic mutation results in constitutive activation of downstream signaling pathways that drive tumor development. In human pancreatic cancer, mutations affecting codon 12 of KRAS (e.g., G12D or G12V) are particularly frequent. In addition, many tumors acquire loss of the tumor suppressor gene TP53 during progression. TP53 normally detects cellular damage and prevents uncontrolled cell proliferation. The combination of activated KRAS and TP53 inactivation represents one of the principal genetic drivers of PDAC.
This exact genetic constellation was reproduced in the mouse models used in the present study. The authors employed established pancreatic cancer models in which an oncogenic KRAS allele is activated in the pancreas while TP53 is mutated or deleted. Such models reproduce key molecular features of human pancreatic cancer and have therefore been widely used in basic cancer research for many years. In addition, orthotopic tumor models and patient-derived xenograft models were included to further validate the findings.
The innovative aspect of the study lies in its therapeutic strategy. Instead of blocking KRAS alone, the researchers simultaneously inhibited multiple signaling pathways that cooperate in KRAS-driven tumors. Specifically, the study tested a triple-combination regimen consisting of: a KRAS inhibitor (daraxonrasib [RMC-6236]), an EGFR/ERBB inhibitor (afatinib), and a STAT3 inhibitor (SD36).
This combination targets different nodes within the same biological signaling network. Tumors often develop escape mechanisms when only a single pathway is inhibited. In the mouse models, the triple therapy resulted in complete tumor regression, and no recurrences were observed over an observation period exceeding 200 days. Such results are unusually strong in preclinical PDAC models and explain the current scientific and media interest.
The study is also noteworthy in the context of recent advances in KRAS-targeted therapies that are currently under clinical development. For decades, KRAS was considered “undruggable.” Only in recent years have effective KRAS inhibitors been developed, initially targeting the KRAS G12C mutation. However, this mutation is relatively rare in pancreatic cancer. Current research therefore increasingly focuses on compounds capable of inhibiting multiple KRAS variants.
The compound used in the present study, daraxonrasib (RMC-6236), belongs to a new generation of RAS(ON) inhibitors that can target several oncogenic KRAS variants. These agents are often referred to as pan-KRAS or pan-RAS inhibitors. Early clinical studies with daraxonrasib have already demonstrated antitumor activity across multiple KRAS-mutant tumor types, including pancreatic cancer.
However, the present study also addresses a key challenge associated with these emerging agents, namely, the development of resistance. Even when KRAS is successfully inhibited, tumor cells may activate alternative signaling pathways to maintain growth. This is precisely where the combination therapy used in the study becomes relevant. By simultaneously blocking KRAS, EGFR, and STAT3, several potential escape mechanisms are suppressed. The findings therefore illustrate a network-based therapeutic strategy aimed at inhibiting an entire signaling network rather than a single molecular target.
Despite these impressive preclinical findings, caution is warranted. Mouse models can reproduce many aspects of human tumor biology, but not all. Important differences exist in: the genetic heterogeneity of tumors, the tumor microenvironment, the immune system, and the pharmacology and toxicity of drugs.
Many therapeutic strategies that showed strong effects in mouse models have subsequently failed to demonstrate clinical benefit in human trials. A well-known example is inhibition of the Hedgehog signaling pathway in pancreatic cancer, which appeared promising in preclinical models but ultimately produced disappointing results in human studies. Moreover, it remains unclear whether the drug combination used in the present study would be tolerable in humans or what dosing strategies would be required.
The most important message of this study is therefore not that a cure for pancreatic cancer is imminent. Rather, the study underscores the critical role of basic research—particularly research using genetically defined mouse models—in advancing our understanding of tumor biology. It also suggests that future therapies may not rely on single-agent activity, but instead on rationally designed combination strategies that simultaneously target key tumor signaling networks.
In summary, the study represents an important scientific advance and provides a compelling preclinical rationale for potential future therapeutic strategies in KRAS-driven pancreatic cancer. At the same time, the findings should be interpreted in the appropriate context: They represent an early but informative step on the long path from basic research to clinical application.